Please login to the form below

Not currently logged in
Email:
Password:

Astellas to close US urology research facility

Work at Urogenix, North Carolina site will end by the end of the year

Astellas is to close its Urogenix urology drug discovery facility in North Carolina, with the loss of 13 jobs, by the end of the year.

The Japanese pharma company acquired the facility from Dynogen Pharmaceuticals in 2006 and gave it a particular focus on researching new treatments for lower urinary tract disorder. 

Astellas will transfer its urology research activities to Astellas' Tsukuba Research Center in Japan and said the decision to shut down the unit would allow it to optimise its research and development resource allocation.

6th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
TVF Communications

At TVF we do things a bit differently – our in-house design and development teams work directly alongside our commercial...

Latest intelligence

london-conferences-anthill.jpg
Meet Anthill at conferences in London
October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit...
Immuno-oncology; bringing patients closer to treatment
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?...
Blog: The role of today’s Regional Business Manager
The importance of delivering brand strategy and supporting people....

Infographics